# Thioredoxin Systems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/thioredoxin-systems

- Industry: Biotechnology
- Headquarters: Stockholm, Sweden
- Website: www.txnsystems.com
- Total disclosed funding: $2.4M
- Latest round: Series A (Oct 30, 2024)
- Investors on record: 4

## About

Founded in 1994 by founder Arne Holmgren and based in Stockholm, Sweden, Thioredoxin Systems AB develops antibiotics for treating multidrug-resistant infections. In October 2024, Thioredoxin Systems AB raised SEK 25 million in series A funding from investors Saminvest AB, GU Ventures, Gobia Enterprises, and Annexstruktur.

The company’s flagship product, EbsArgent, is an antibiotic regimen for addressing complicated urinary tract infections (cUTIs) caused by antibiotic-resistant bacteria. The product employs a mechanism of action that disrupts bacterial antioxidant redox systems against a broad spectrum of pathogens.

The company will use the October 2024 funding to accelerate the development of its EbsArgent bactericidal antibiotic for urinary tract infections (UTIs).

## Funding rounds

- Series A, Oct 30, 2024, $2.4M — Saminvest, GU Ventures, Gobia Enterprises, Annexstruktur

## Investors

- Saminvest (https://capitalatlas.ai/funds/saminvest) — Series A
- GU Ventures (https://capitalatlas.ai/funds/gu-ventures) — Series A
- Gobia Enterprises — Series A
- Annexstruktur — Series A